Jasper Therapeutics (JSPR) vs Quince Therapeutics (QNCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jasper Therapeutics (JSPR) has outperformed Quince Therapeutics (QNCX) over the past year, losing 76.7% versus a loss of 92.4%. Over five years, JSPR leads with a -99.7% price change compared with -99.8% for QNCX. Quince Therapeutics is the larger company by market cap ($29.9 million vs $18.6 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JSPR | QNCX |
|---|---|---|
| Share price | $0.56 | $29.36 |
| Market cap | $18.63M | $29.86M |
| 1-day change | -1.70% | +9.88% |
| YTD return | -69.40% | -95.62% |
| 1-year return | -76.67% | -92.35% |
| 5-year return | -99.66% | -99.77% |
| EPS (TTM) | $-1.04 | $-214.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.69 | $910.00 |
| 52-week low | $0.315 | $15.10 |
| Distance from 52-week high | -79.18% | -96.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +3471.43% | +156.91% |
| Average volume | 1.37M | 28.49K |
| Shares outstanding | 33.27M | 1.02M |
| Employees | — | 38 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JSPR has outperformed QNCX by 15.7 percentage points over the past year.
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Healthcare · Biotechnology
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Healthcare · Biotechnology · 38 employees
JSPR vs QNCX FAQ
Which is bigger, Jasper Therapeutics or Quince Therapeutics?
Quince Therapeutics (QNCX) is larger, with a market capitalization of $29.86M compared with $18.63M for Jasper Therapeutics (JSPR).
Which stock has performed better over the past year, JSPR or QNCX?
JSPR returned -76.67% over the past 12 months, compared with -92.35% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are Jasper Therapeutics and Quince Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.